Pharmaceutical Executive, Nov 1, 2011 - Pharmaceutical Executive

ADVERTISEMENT

Pharmaceutical Executive, Nov 1, 2011
Features
The Rx Club's 25th Anniversary Show
By Jennifer Ringler , Ben Comer
Over 25 years the Rx Club Show has reflected dramatic technological changes in advertising. But, as always, the subject comes first, the medium second. So where did the accolades go this year?
Prix Galien USA 2011
By Jeff Schindler
A celebration of achievement
Does a German Launch Make Sense?
Will the structure and ambiguity of Germany's new medicines pricing system bring a halt to new drug launches in Europe's largest market?
Back Page
Fostering a Legacy of Leadership
By Jeff Schindler
Pharm Exec's 2011 Emerging Leaders celebration convened Oct. 6 in New York.
Column
The Drug Shortages Struggle
By Jill Wechsler
Clamor for critical therapies prompts probes of prices, production practices.
Spotlight on OTCs
With OTCs challenging traditional approaches to quality, new opportunities are arising to support industry innovation and advance public health.
Pharma's Visit to the Plastic Surgeon
By Bill Drummy
The bigger the company, the thicker the sclerosis, the more they need to suck out the fat
The Pharma Revolution Recalibrated
Industry critics point to a lag in NME approvals as proof of innovation stagnation, but combination products and new delivery systems are quietly saving lives, and bringing in big dollars.
Europe Tackles 'Advertising in Disguise' Fears
By Julian Upton
The EC's latest proposals have thrown water on Europe's firey Direct-to-Consumer advertising debate. But is it enough to keep the flames at bay?
Agency Assignments: Managing the Hidden Costs
By Al Topin
Saving the agency/client relationship begins first with the people involved and defining accountability on both sides
From the Editor
R&D Costs: It's Industry's Problem
By William Looney
If high prices that lower access are attributable to a flawed R&D model, can industry embrace delivering better results at lower costs.

ADVERTISEMENT

Click here